Diabetic Dyslipidemia

Endocrinology and Metabolism Clinics of North America

Volumn 35, Issue 3, 2006, Pages 491-510

  Chahil, Tina J ^a   Ginsberg, Henry N ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; APOLIPOPROTEIN; ATORVASTATIN; CHYLOMICRON; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PRAVASTATIN; ROSIGLITAZONE; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE EXACERBATION; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE;

CARDIOVASCULAR DISEASES; CHYLOMICRONS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; LIVER; PARTICLE SIZE; RISK FACTORS;

EID: 33748415924     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2006.06.002     Document Type: Review

References (76)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005 (2005), US Department of Health and Human Services. Centers for Disease Control and Prevention, Atlanta (GA)
2. Grundy S.M., Benjamin I.J., Burke G.L., et al. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 100 (1999) 1134-1146
3. Morrish N.J., Wang S.-L., Stevens L.K., et al., the WHO Multinational Study Group. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 44 Suppl 2 (2001) S14-S21
4. Stamler J., Vaccaro O., Neaton J.D., et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16 2 (1993) 434-444
5. Beckman J.A., Creager M.A., and Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 19 (2002) 2570-2581
6. Whiteley L., Padmanabhan S., Hole D., et al. Should diabetes be considered a coronary heart disease risk equivalent? Results from 25 years of follow-up in the Renfrew and Paisley survey. Diabetes Care 28 7 (2005) 1588-1593
7. Haffner S.M., Lehto S., Rönnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 4 (1998) 229-234
8. Becker A., Bos G., de Vegt F., et al. Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn study. Eur Heart J 24 (2003) 1406-1413
9. Miettinen H., Lehto S., Salomaa V., et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA myocardial infarction register study group. Diabetes Care 21 1 (1998) 69-75
10. Howard B.V., Rodriguez B.L., Bennett P.H., et al. Prevention conference VI. Diabetes and cardiovascular disease writing group I: epidemiology. Circulation 105 (2002) e132-e137
11. Mak K.-H., and Haffner S.M. Diabetes abolishes the gender gap in coronary heart disease. Eur Heart J 24 (2003) 1385-1386
12. Howard B.V., Cowan L.D., Go O., et al., for the Strong Heart Study investigators. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. The Strong Heart Study. Diabetes Care 21 8 (1998) 1258-1265
13. Juutilainen A., Kortelainen S., Lehto S., et al. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care 27 12 (2004) 2898-2904
14. Ginsberg H.N. Lipoprotein physiology in nondiabetic and diabetic states: relationship to atherogenesis. Diabetes Care 14 (1991) 839-855
15. Kreisberg R.A. Diabetic dyslipidemia. Am J Cardiol 82 (1998) 67U-73U
16. Haffner S.M. Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance. Am J Cardiol 90 suppl (2002) 55i-61i
17. Ebara T., Conde K., Kako Y., et al. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J Clin Invest 105 12 (2000) 1807-1818
18. Brunzell J.D. Increased ApoB in small dense LDL particles predicts premature coronary artery disease. Arterioscler Thromb Vasc Biol 25 3 (2005) 474-475
19. Krauss R.M. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27 6 (2004) 1496-1504
20. Sacks F.M., and Campos H. Clinical review 163: Cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 88 10 (2003) 4525-4532
21. Haidari M., Leung N., Mahbub F., et al. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J Biol Chem 277 (2002) 31646-31655
22. Pennacchio L.A., and Rubin E.M. Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. Arterioscler Thromb Vasc Biol 23 4 (2003) 529-534 [Epub 2002 Dec]
23. Cianflone K., Xia Z., and Chen L.Y. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 1609 2 (2003) 127-143
24. Merkel M., Eckel R.H., and Goldberg I.J. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 43 (2002) 1997-2006
25. Altomonte J., Cong L., Harbaran S., et al. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 114 (2004) 1493-1503
26. Cohn J.S., Patterson B.W., Uffelman K.D., et al. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J Clin Endocrinol Metab 89 (2004) 3949-3955
27. Nowak M., Helleboid-Chapman A., Jakel H., et al. Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Mol Cell Biol 25 4 (2005) 1537-1548
28. Brunzell J.D., Hazzard W.R., Porte Jr. D., et al. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest 52 7 (1973) 1578-1585
29. Bjorkegren J., Packard C.J., Hamsten A., et al. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J Lipid Res 37 (1996) 76-86
30. Shachter N. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 12 3 (2001) 297-304
31. Kissebah A.H. Low density lipoprotein metabolism in non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 3 (1987) 619-651
32. Zambon A., Bertocco S., Vitturi N., et al. Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins. Biochem Soc Trans 31 (2003) 1070-1074
33. Ginsberg H.N., and Illingworth D.R. Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. Am J Cardiol 88 suppl (2001) 9H-15H
34. Olofsson S.O., Stillemark-Billton P., and Asp L. Intracellular assembly of VLDL: two major steps in separate cell compartments. Trends Cardiovasc Med 10 (2000) 338-345
35. Fisher E.A., and Ginsberg H.N. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem 277 (2002) 17377-17380
36. Fisher E.A., Pan M., Chen X., et al. The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways. J Biol Chem 276 30 (2001) 27855-27863
37. Ginsberg H.N. Insulin resistance and cardiovascular disease. J Clin Invest 106 (2000) 453-458
38. Kissebah A.H., Alfarsi S., Adams P.W., et al. Role of insulin resistance in adipose tissue and liver in the pathogenesis of endogenous hypertriglyceridaemia in man. Diabetologia 12 (1976) 563-571
39. Lewis G.F. Fatty acid regulation of very low density lipoprotein (VLDL) production. Curr Opin Lipidol 10 (1999) 475-477
40. Zhang Y., Ono-Hernandez A., Ko C., et al. Regulation of hepatic lipoprotein assembly and secretion by the availability of fatty acids. I: Differential responses to the delivery of fatty acids via albumin or remnant-like emulsion particles. J Biol Chem 279 (2004) 19362-19374
41. Craig W.Y., Nutik R., and Cooper A.D. Regulation of apoprotein synthesis and secretion in the human hepatoma Hep G2. The effect of exogenous lipoprotein. J Biol Chem 263 (1988) 13880-13890
42. Cohn J.S., Wagner D.A., Cohn S.D., et al. Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J Clin Invest 85 (1990) 804-811
43. Schwarz J.M., Linfoot P., Dare D., et al. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 77 (2003) 43-50
44. Donnelly K.L., Smith C.I., Schwarzenberg S.J., et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115 5 (2005) 1343-1351
45. Horton J.D., Goldstein J.L., and Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acidsynthesis in the liver. J Clin Invest 109 (2002) 1125-1131
46. Shimomura I., Matsuda M., Hammer R.E., et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 6 (2000) 77-86
47. Siri P., Candela N., Ko C., et al. Post-transcriptional stimulation of the assembly and secretion of triglyceride-rich apolipoproteinB-lipoproteins in a mouse with selective deficiency of brown adipose tissue, obesity and insulin resistance. J Biol Chem 276 (2001) 46064-46072
48. Sparks J.D., and Sparks C.E. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta 1215 1-2 (1994) 9-32
49. Pan M., Cederbaum A.I., Zhang Y.-L., et al. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest 113 (2004) 1277-1288
50. Lewis G.F., Uffelman K.D., Szeto L.W., et al. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 42 (1993) 833-842
51. Malmstrom R., Packard C.J., Caslake M., et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 40 (1997) 454-462
52. Austin M.A., and Krauss R.M. LDL density and atherosclerosis. JAMA 273 (1995) 115
53. Krauss R.M., and Siri P.W. Metabolic abnormalities: triglyceride and low-density lipoprotein. Endocrinol Metab Clin North Am 33 2 (2004) 405-415
54. Lewis G.F., and Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96 12 (2005) 1221-1232
55. Oram J.F., and Heinecke J.W. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 85 4 (2005) 1343-1372
56. Wang N., Lan D., Chen W., et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 101 26 (2004) 9774-9779
57. Stein O., and Stein Y. Lipid transfer proteins (LTP) and atherosclerosis. Atherosclerosis 178 2 (2005) 217-230
58. Horowitz B.S., Goldberg I.J., Merab J., et al. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 91 (1993) 1743-1760
59. Cleeman J.I., Expert Panel on Detection, Evaluation, and and Treatment of High Blood Cholesterol In Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 19 (2001) 2486-2497
60. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. NIH Publication No. 02-5215. Circulation 106 25 (2002) 3143-3421
61. LaRosa J.C., Grundy S.M., and Waters D.D. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
62. Rubins H.B., Robbins S.J., Collins P., et al., for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
63. Keech A., Simes R.J., Barter P., et al., for the FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 9500 (2005) 1849-1861
64. Meyers C.D., and Kashyap M.L. Management of the metabolic syndrome-nicotinic acid. Endocrinol Metab Clin North Am 33 (2004) 557-575
65. Goldberg R.B., Kendall D.M., Deeg M.A., et al., for the GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 7 (2005) 1547-1554
66. Dormandy J.A., Charbonnel B., Eckland D.J., et al., for the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 9493 (2005) 1279-1289
67. Wei M., Gaskill S.P., Haffner S.M., et al. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 21 7 (1998) 1167-1172
68. Siegel R.D., Cupples A., Schaefer E.J., et al. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham Offspring Study. Metabolism 45 10 (1996) 1267-1272
69. Pyörälä K., Pedersen T.R., Kjekshus J., et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20 (1997) 614-620
70. Haffner S.M., Alexander C.M., Cook T.J., et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 159 (1999) 2661-2667
71. Goldberg R.B., Mellies M.J., Sacks F.M., et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation 98 (1998) 2513-2519
72. Keech A., Colquhoun D., Best J., et al., for the LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 26 (2003) 2713-2721
73. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
74. Sever P.S., Dahlöf B., Poulter N.R., et al., for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1157
75. Colhoun H.M., Betteridge D.J., Durrington P.N., et al., for the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
76. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986) 1245-1255